The EC approved Merck's Keytruda plus Padcev as perioperative treatment for resectable MIBC, the first PD-1+ADC regimen in the EU for patients regardless of cisplatin eligibility. The KEYNOTE-B15 trial showed a 47% reduction in EFS risk and 35% reduction in OS risk versus neoadjuvant chemo plus surgery. FDA approved the same regimen in July 2026.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
